Effect of Data Selection on Reimbursement Decisions. Breast Cancer Case
Journal Title:Acta Scientific Women's Health
One of the daily challenges for health care policy makers is selecting the right patient for the right treatment with affordable price. If we taking breast cancer treatments at law middle income country, as Egypt's experience with breast cancer, an incidence (15.4) per 100,000 beside the prevalence of HER2-positive breast cancer is approximately 15% to 20% of primary breast cancers. this will lead to economic burden as well as consequences on decision makers. When they decides to treat with monoclonal antibodies like Trastuzumab what is the appropriate time to treat the patient to achieve the efficient management of resources 6 months versus 12 months of adjuvant Trastuzumab in early breast cancer. What will be the best option for the resources and patients outcomes?To answer the previous question an economic study was conducted trying to support decisions makers. The result of economic model showed that selecting one clinical study for deciding shorter time regimen versus standard regimen is might not be strong evidence for taking the decisions because the economic model was so sensitive to the following parameters. Selecting data for health care decision making in oncology should take in consideration.Strength of evidence sensitivity analysis of that data should be conducted to ensure effective health care decisions and losing the previous criteria might lead to negative impact on patients’ outcomes and treatment resources.